| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
101,000,000 |
| Market
Cap: |
782.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.7528 - $16.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 9.5 |
| Insider 3/6 Months : 10.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
230,000 |
330,000 |
330,000 |
| Total Buy Value |
$0 |
$310,500 |
$455,990 |
$455,990 |
| Total People Bought |
0 |
2 |
3 |
3 |
| Total Buy Transactions |
0 |
2 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
| Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
1 |
9 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chalberg Thomas W. |
Chief Executive Officer |
• • – |
2015-05-05 |
4 |
AS |
$30.00 |
$750,093 |
D/D |
(25,000) |
283,988 |
|
- |
|
| Bain Linda |
Chief Financial Officer |
• – – |
2015-05-04 |
4 |
AS |
$31.59 |
$78,972 |
D/D |
(2,500) |
9,000 |
|
- |
|
| Bain Linda |
Chief Financial Officer |
• – – |
2015-05-04 |
4 |
OE |
$3.15 |
$7,875 |
D/D |
2,500 |
11,500 |
|
- |
|
| Wachter Paul |
Director |
– • – |
2015-05-04 |
4 |
AS |
$30.87 |
$36,797 |
I/I |
(1,192) |
44,313 |
|
- |
|
| Hull Hans |
SVP, Business Operations |
• – – |
2015-05-04 |
4 |
AS |
$30.87 |
$154,349 |
D/D |
(5,000) |
11,320 |
|
- |
|
| Hull Hans |
SVP, Business Operations |
• – – |
2015-05-04 |
4 |
OE |
$0.19 |
$950 |
D/D |
5,000 |
16,320 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2015-05-01 |
4 |
AS |
$32.37 |
$647,306 |
D/D |
(20,000) |
577,989 |
|
- |
|
| Gasmi Mehdi |
VP, Pharmaceutical Development |
• – – |
2015-04-28 |
4 |
AS |
$35.67 |
$35,667 |
D/D |
(1,000) |
7,000 |
|
- |
|
| Gasmi Mehdi |
VP, Pharmaceutical Development |
• – – |
2015-04-28 |
4 |
OE |
$2.75 |
$2,750 |
D/D |
1,000 |
8,000 |
|
- |
|
| Wachter Paul |
Director |
– • – |
2015-04-27 |
4 |
AS |
$35.61 |
$42,443 |
I/I |
(1,192) |
45,505 |
|
- |
|
| Schwartz Steven Daniel |
Director |
– • – |
2015-04-23 |
4 |
AS |
$38.62 |
$651,665 |
D/D |
(16,875) |
436,181 |
|
- |
|
| Rubio Roman G. |
SVP, Translational Medicine |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
|
- |
|
| Schwartz Steven Daniel |
Director |
– • – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
453,056 |
|
- |
|
| Hull Hans |
SVP, Business Operations |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
11,320 |
|
- |
|
| Barone Samuel B. |
Chief Medical Officer |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
|
- |
|
| Mclaughlin John Peter |
Director |
– • – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Wachter Paul |
Director |
– • – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
|
- |
|
| Gasmi Mehdi |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
7,000 |
|
- |
|
| Gasmi Mehdi |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
AS |
$39.21 |
$39,211 |
D/D |
(1,000) |
0 |
|
- |
|
| Gasmi Mehdi |
VP, Pharmaceutical Development |
• – – |
2015-04-21 |
4 |
OE |
$2.75 |
$2,750 |
D/D |
1,000 |
1,000 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
597,989 |
|
- |
|
| Chalberg Thomas W. |
Chief Executive Officer |
• • – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
308,988 |
|
- |
|
| Bain Linda |
Chief Financial Officer |
• – – |
2015-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Wachter Paul |
Director |
– • – |
2015-04-20 |
4 |
AS |
$40.19 |
$47,910 |
I/I |
(1,192) |
46,697 |
|
- |
|
| Blumenkranz Mark S. |
Director |
– • – |
2015-04-16 |
4 |
AS |
$41.59 |
$1,039,753 |
D/D |
(25,000) |
595,989 |
|
- |
|
266 Records found
|
|
Page 9 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (2.15%) 
